免疫治疗与化疗联合应用于中晚期非小细胞肺癌治疗的效果分析  

Curative Value Research of Immunotherapy Combined with Chemotherapy in Treatment of Advanced Non-Small Cell Lung Cancer

作　　者：潘钰娇 肖永平 李柯 PAN Yujiao;XIAO Yongping;LI Ke(Department of Oncology,Wuwei Tumor Hospital,Wuwei,Gansu 733000;Biological Immunotherapy Room,Wuwei Tumor Hospital,Wuwei,Gansu 733000;PET-CT Room,Wuwei Tumor Hospital,Wuwei,Gansu 733000)

机构地区：[1]甘肃武威肿瘤医院肿瘤内科,甘肃武威733000 [2]甘肃武威肿瘤医院生物免疫治疗室,甘肃武威733000 [3]甘肃武威肿瘤医院PET-CT室,甘肃武威733000

出　　处：《智慧健康》2024年第20期53-56,共4页Smart Healthcare

摘　　要：目的分析免疫治疗联合化疗治疗中晚期非小细胞肺癌(NSCLC)的效果。方法选取2022年8月—2023年8月本院收治的58例中晚期NSCLC患者开展研究,用随机数字表法将其分为对照组(n=29)和观察组(n=29)。对照组行单一化疗,观察组行化疗联合免疫治疗,比较两组临床疗效。结果治疗后,观察组的CD4+百分率明显高于对照组,CD8+百分率、CD3+百分率明显低于对照组(P<0.05);观察组肿瘤标志物水平明显低于对照组(P<0.05);观察组典型症状积分明显低于对照组(P<0.05);观察组治疗有效率明显高于对照组(P<0.05)。结论给予中晚期NSCLC患者免疫联合化疗治疗能有效抑制肿瘤进展,改善免疫反应,减轻病情,加强疗效,具有推广价值。Objective To analyze effect of immunotherapy combined with chemotherapy in treatment of advanced non-small cell lung cancer(NSCLC).Methods The paper chose 58 patients with advanced NSCLC in our hospital from August 2022 to August 2023,and randomly divided them into control group of 29 cases treated with single chemotherapy,and observation group of 29 cases with combined immunotherapy.Clinical effect between two groups was compared.Results CD4+level and treatment effective rate in observation group were significantly higher than control group,and CD8+,CD3+,CA125,CEA,SCC-Ag,CYFRA211,scores of shortness of breath,fever,fatigue,blood phlegm,chest pain,and cough were significantly lower than control group(P<0.05).Conclusion Immunotherapy combined with chemotherapy can inhibit tumor progression,improve immune response,alleviate condition,enhance curative effect of patients with advanced NSCLC effectively,which has promotional value.

关 键 词：免疫治疗 化疗 非小细胞肺癌 肿瘤因子 

分 类 号：R734.2[医药卫生—肿瘤]